Welcome to Helix Talk, an educational podcast for healthcare students and providers covering real-life clinical pearls, professional pharmacy topics, and drug therapy discussions.

This podcast is provided by pharmacists and faculty members at Rosal Franklin University College of Pharmacy.

This podcast contains general information for educational purposes only. This is not

professional advice and should not be used in lieu of obtaining advice from a qualified health

care provider. And now on to the show. Welcome to Helix Talk episode 67. I'm your co-host,

Dr. Kaine. I'm Dr. Sherman. And I'm Dr. Patel.

And continuing the talk of diabetes, today we're going to talk even further.

The topic of our discussion today is diabetes, does it cost a heart and a leg?

So if you listen to our episode number 35, we discuss the cardiovascular outcomes of Empaglophosin, a brand name Jardians.

That was one of the Mase trial, and it showed that impaglophosin was actually superior than

the placebo.

And as a result, the ADA guidelines of 2017 standards of care has adopted the recommendation

to use impagoposin in patients with diabetes who have established

cardiovascular disease or are at a higher risk of having cardiovascular disease.

And so today we're going to talk about some of similar trials that have become available since

Empaglophosin trial, then park trial. And the first and the foremost is

the leader trial. Now this was, as you would expect, a multi-centered double-blind placebo-controlled

trial done in a number of different countries, included more than 9,000 patients who were type 2

diabetics, all of which had an A1C above 7%. And they assigned

them to either laryglotide, that was 1.8 milligrams or whatever max-tolerated dose they had,

versus placebo. And they did this after a two-week run-in period. And then they followed them for

42 to 60 weeks. And the running period was just there to make sure patients were okay injecting the medication

...